Total Payments
$733,259
2024 Payments
$63,818
Companies
51
Transactions
1,305
Medicare Patients
1,690
Medicare Billing
$112,927
Payment Breakdown by Category
Other$388,965 (53.0%)
Travel$165,620 (22.6%)
Consulting$148,567 (20.3%)
Food & Beverage$27,185 (3.7%)
Research$2,497 (0.3%)
Education$423.56 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $334,773 | 176 | 45.7% |
| Travel and Lodging | $165,620 | 193 | 22.6% |
| Consulting Fee | $148,567 | 41 | 20.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $32,747 | 13 | 4.5% |
| Food and Beverage | $27,185 | 849 | 3.7% |
| Honoraria | $16,695 | 10 | 2.3% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $4,750 | 2 | 0.6% |
| Unspecified | $2,497 | 5 | 0.3% |
| Education | $423.56 | 16 | 0.1% |
Payments by Type
General
$730,762
1,300 transactions
Research
$2,497
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $470,048 | 447 | $0 (2024) |
| Novo Nordisk AS | $126,341 | 60 | $0 (2024) |
| Dexcom, Inc. | $71,231 | 118 | $0 (2024) |
| Insulet Corporation | $20,299 | 73 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $14,503 | 19 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $8,091 | 46 | $0 (2024) |
| Tandem Diabetes Care, Inc. | $5,970 | 53 | $0 (2024) |
| VERTEX PHARMACEUTICALS INCORPORATED | $4,725 | 6 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $2,178 | 3 | $0 (2024) |
| Lilly USA, LLC | $1,685 | 94 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,818 | 90 | Novo Nordisk Inc ($27,769) |
| 2023 | $50,348 | 58 | Novo Nordisk AS ($20,447) |
| 2022 | $79,430 | 142 | Novo Nordisk Inc ($68,484) |
| 2021 | $57,788 | 123 | Novo Nordisk Inc ($44,701) |
| 2020 | $42,338 | 74 | Novo Nordisk Inc ($17,705) |
| 2019 | $141,779 | 251 | Novo Nordisk Inc ($101,169) |
| 2018 | $164,722 | 298 | Novo Nordisk Inc ($100,968) |
| 2017 | $133,036 | 269 | Novo Nordisk Inc ($97,211) |
All Payment Transactions
1,305 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 12/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $94.54 | General |
| Category: Endocrinology | ||||||
| 11/14/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 11/07/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $1,109.68 | General |
| Category: Endocrinology | ||||||
| 11/05/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 10/01/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $96.90 | General |
| Category: Endocrinology | ||||||
| 09/24/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $1,227.64 | General |
| Category: Endocrinology | ||||||
| 09/19/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,437.50 | General |
| 09/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $121.12 | General |
| 09/18/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 08/29/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 08/28/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Diabetes | ||||||
| 08/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Diabetes | ||||||
| 08/23/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Endocrinology | ||||||
| 08/22/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 08/22/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: Diabetes Care | ||||||
| 08/21/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $383.00 | General |
| Category: Endocrinology | ||||||
| 08/19/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 08/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $5.40 | General |
| Category: Diabetes | ||||||
| 07/29/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.58 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LX9211 | Lexicon Pharmaceuticals, Inc. | $2,178 | 3 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 | SANOFI-AVENTIS U.S. LLC | $319.31 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 262 | 277 | $34,270 | $10,695 |
| 2022 | 8 | 667 | 996 | $131,660 | $57,270 |
| 2021 | 9 | 441 | 617 | $73,642 | $31,327 |
| 2020 | 8 | 320 | 400 | $38,457 | $13,636 |
Total Patients
1,690
Total Services
2,290
Medicare Billing
$112,927
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 66 | $16,500 | $5,449 | 33.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 47 | $8,742 | $2,993 | 34.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 74 | 79 | $6,478 | $1,480 | 22.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 82 | 85 | $2,550 | $773.08 | 30.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 156 | 238 | $59,500 | $30,189 | 50.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 92 | $17,112 | $7,429 | 43.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 145 | 266 | $22,003 | $6,547 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $11,745 | $5,420 | 46.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 37 | 40 | $7,440 | $2,968 | 39.9% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 170 | 267 | $8,010 | $2,558 | 31.9% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 14 | 15 | $4,095 | $1,446 | 35.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 37 | 45 | $1,755 | $712.37 | 40.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 65 | 89 | $16,554 | $7,468 | 45.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 82 | $15,252 | $7,177 | 47.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 51 | $12,750 | $6,802 | 53.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 92 | 170 | $13,940 | $4,262 | 30.6% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 13 | 17 | $4,641 | $1,687 | 36.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 24 | 24 | $3,048 | $1,440 | 47.3% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 94 | 135 | $4,050 | $1,301 | 32.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 17 | $2,159 | $702.13 | 32.5% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 24 | 32 | $1,248 | $487.20 | 39.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 58 | 64 | $11,904 | $5,107 | 42.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 60 | 103 | $8,446 | $2,723 | 32.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 36 | 39 | $4,953 | $1,968 | 39.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 37 | 38 | $6,138 | $1,512 | 24.6% |
About Dr. Wendy Lane, MD
Dr. Wendy Lane, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Asheville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1073644175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wendy Lane, MD has received a total of $733,259 in payments from pharmaceutical and medical device companies, with $63,818 received in 2024. These payments were reported across 1,305 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($334,773).
As a Medicare-enrolled provider, Lane has provided services to 1,690 Medicare beneficiaries, totaling 2,290 services with total Medicare billing of $112,927. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Public Health & General Preventive Medicine
- Location Asheville, NC
- Active Since 03/08/2007
- Last Updated 08/05/2013
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1073644175
Products in Payments
- Tresiba (Drug) $179,644
- Ozempic (Drug) $112,653
- Victoza (Drug) $95,443
- Rybelsus (Drug) $36,468
- RYBELSUS (Drug) $31,722
- DEXCOM G7 GSS (161) (Medical Supply) $31,308
- Omnipod (Device) $20,299
- Dexcom CGM (Device) $15,982
- GVOKE PFS (Drug) $14,451
- Xultophy 100/3.6 (Drug) $11,394
- Dexcom G6 Transmitter (Medical Supply) $9,548
- NO PRODUCT DISCUSSED (Drug) $6,953
- DEXCOM G6 TRANSMITTER (Device) $6,911
- DEXCOM G6 CGM SYSTEM (Device) $6,515
- t-slim insulin pump (Device) $5,548
- FIASP (Drug) $3,420
- ZEGALOGUE (Drug) $1,622
- HUMULIN (Drug) $891.02
- FARXIGA (Drug) $786.62
- Repatha (Biological) $737.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Asheville
Richard Dodd, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $924,614
Endocrinology, Diabetes & Metabolism $924,614
Dr. Victor Marlar, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $815,366
Endocrinology, Diabetes & Metabolism $815,366
Lauren Bernstein, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $280,697
Endocrinology, Diabetes & Metabolism $280,697
David Hester, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $23,730
Endocrinology, Diabetes & Metabolism $23,730
Stephen Weinrib, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $16,625
Endocrinology, Diabetes & Metabolism $16,625
Dr. Brian Cumbie, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $9,320
Endocrinology, Diabetes & Metabolism $9,320